These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31775909)

  • 41. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
    Jarnicki AG; Lysaght J; Todryk S; Mills KH
    J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
    Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
    Front Immunol; 2020; 11():1885. PubMed ID: 33042110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
    Yue C; Shen S; Deng J; Priceman SJ; Li W; Huang A; Yu H
    Cancer Immunol Res; 2015 Aug; 3(8):864-870. PubMed ID: 26025380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
    Rosenblum JM; Shimoda N; Schenk AD; Zhang H; Kish DD; Keslar K; Farber JM; Fairchild RL
    J Immunol; 2010 Apr; 184(7):3450-60. PubMed ID: 20194716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer.
    Deng S; Deng Q; Zhang Y; Ye H; Yu X; Zhang Y; Han GY; Luo P; Wu M; Yu Y; Han W
    Cancer Lett; 2019 Feb; 443():1-12. PubMed ID: 30481563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
    Wang D; Yang L; Yu W; Wu Q; Lian J; Li F; Liu S; Li A; He Z; Liu J; Sun Z; Yuan W; Zhang Y
    J Immunother Cancer; 2019 Aug; 7(1):215. PubMed ID: 31395078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile.
    Löfroos AB; Kadivar M; Resic Lindehammer S; Marsal J
    Eur J Med Res; 2017 Oct; 22(1):40. PubMed ID: 29020986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets.
    van Herk EH; Te Velde AA
    J Gastroenterol Hepatol; 2016 Aug; 31(8):1393-404. PubMed ID: 26990130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.
    Yang X; Zhao J; Duan S; Hou X; Li X; Hu Z; Tang Z; Mo F; Lu X
    Theranostics; 2019; 9(14):4066-4083. PubMed ID: 31281532
    [No Abstract]   [Full Text] [Related]  

  • 50. Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells.
    Scurr M; Ladell K; Besneux M; Christian A; Hockey T; Smart K; Bridgeman H; Hargest R; Phillips S; Davies M; Price D; Gallimore A; Godkin A
    Mucosal Immunol; 2014 Mar; 7(2):428-39. PubMed ID: 24064667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
    Guo L; Wang C; Qiu X; Pu X; Chang P
    Front Immunol; 2020; 11():1052. PubMed ID: 32547556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.
    Wang S; Kuai Y; Lin S; Li L; Gu Q; Zhang X; Li X; He Y; Chen S; Xia X; Ruan Z; Lin C; Ding Y; Zhang Q; Qi C; Li J; He X; Pathak JL; Zhou W; Liu S; Wang L; Zheng L
    BMC Med; 2023 Mar; 21(1):115. PubMed ID: 36978108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
    Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of LAP
    Zhong W; Jiang ZY; Zhang L; Huang JH; Wang SJ; Liao C; Cai B; Chen LS; Zhang S; Guo Y; Cao YF; Gao F
    World J Gastroenterol; 2017 Jan; 23(3):455-463. PubMed ID: 28210081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
    Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
    Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The anti-tumor effects of CT-26 derived exosomes enriched by MicroRNA-34a on murine model of colorectal cancer.
    Hosseini M; Baghaei K; Hajivalili M; Zali MR; Ebtekar M; Amani D
    Life Sci; 2022 Feb; 290():120234. PubMed ID: 34953890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
    Saito T; Nishikawa H; Wada H; Nagano Y; Sugiyama D; Atarashi K; Maeda Y; Hamaguchi M; Ohkura N; Sato E; Nagase H; Nishimura J; Yamamoto H; Takiguchi S; Tanoue T; Suda W; Morita H; Hattori M; Honda K; Mori M; Doki Y; Sakaguchi S
    Nat Med; 2016 Jun; 22(6):679-84. PubMed ID: 27111280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing the role of IL-35 in colorectal cancer progression and prognosis.
    Zeng JC; Zhang Z; Li TY; Liang YF; Wang HM; Bao JJ; Zhang JA; Wang WD; Xiang WY; Kong B; Wang ZY; Wu BH; Chen XD; He L; Zhang S; Wang CY; Xu JF
    Int J Clin Exp Pathol; 2013; 6(9):1806-16. PubMed ID: 24040445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.